BIXT

distress 3/10 · well-funded / low risk

$0.02-2%today-77% from 52w high

bioxytraninc.com2 employeesFounded 2008Needham, MABiotechnology

Revenue

pre-revenue

Liquidity

$0M

Runway

—

Shares 1y

+28%

Price & events

-56.8% over 6M

CatalystRating changeDilutionFinancingdashed = today

-1.7%

-1.8%

-14.5%

-34.1%

-56.8%

-73.6%

-80.8%

+112.3%

-90.1%

All

Overview

Market Cap: $2.72M
Volume: 53.00K
52 Week Range: $0.02 – $0.10
Total Shares: 114.20M
Float Shares: 113.49M
% Held by Insiders: 0.62%
% Held by Institutions: 0.00%
RVOL: 1.39x
Beta: 1.93

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 4

2026-02-10partnershipA-SUQAR · Commercial distribution agreement with Khoury Medical LTD for A-SUQAR dietary supplementSEC 8-K
2025-01-15partnershipSecured $1.6M common stock purchase agreement with Triton Funds LP and management forfeited $460K in accrued salariesSEC 8-K
2024-10-25partnershipProLectin-M · Acquisition of NDPD Pharma, including patents for treating viral infections.SEC 8-K
2024-07-15partnershipUniversal Oxygen Carrier · Joint venture with Heme Foundation and NDPD Pharma to develop UOC; Heme Foundation pledges up to $10M.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 114,195,220 · 0 offerings/1y · 1 PIPEs

2026-03-208-Kprivate_placement
2026-02-178-Kmaterial_agreement
2025-02-18424B4offering
2025-02-14EFFECTshelf_effective
2025-02-12S-1/Ashelf_registration
2025-02-05S-1/Ashelf_registration
2025-01-228-Kmaterial_agreement

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors

none identified